Close
  Indian J Med Microbiol
 

Figure 4: (a) PANSS total, (b) PANSS positive, (c) PANSS negative, (d) PANSS general psychopathology, and (e) CGI-S in mean change from baseline to last observation carried forward (LOCF) endpoint using modal daily dose. *p < 0.05; **p < 0.01; ***p < 0.001, significantly different for change from baseline using Wilcoxon signed rank test or between modal daily doses (MDDs) using Steel–Dwass test. MDDs in (a) were 40 or 80 mg/day (n = 30), 120 mg/day (n = 13), and 160 mg/day (n = 11). MDDs in (b) were 40 or 80 mg/day (n = 30), 120 mg/day (n = 13), 160 mg/day (n = 11). MDDs in (c) were 40 or 80 mg/day (n = 30), 120 mg/day (n = 13), and 160 mg/day (n = 11). MDDs in (d) were 40 or 80 mg/day (n = 30), 120 mg/day (n = 13), and 160 mg/day (n = 11). MDDs in (e) were 40 or 80 mg/day (n = 30), 120 mg/day (n = 13), 160 mg/day (n = 11). ns, not significant; PANSS, positive and negative syndrome scale.

Figure 4:  (a) PANSS total, (b) PANSS positive, (c) PANSS negative, (d) PANSS general psychopathology, and (e) CGI-S in mean change from baseline to last observation carried forward (LOCF) endpoint using modal daily dose. *<i>p</i> < 0.05; **<i>p</i> < 0.01; ***<i>p</i> < 0.001, significantly different for change from baseline using Wilcoxon signed rank test or between modal daily doses (MDDs) using Steel–Dwass test. MDDs in (a) were 40 or 80 mg/day (<i>n</i> = 30), 120 mg/day (<i>n</i> = 13), and 160 mg/day (<i>n</i> = 11). MDDs in (b) were 40 or 80 mg/day (<i>n</i> = 30), 120 mg/day (<i>n</i> = 13), 160 mg/day (<i>n</i> = 11). MDDs in (c) were 40 or 80 mg/day (<i>n</i> = 30), 120 mg/day (<i>n</i> = 13), and 160 mg/day (<i>n</i> = 11). MDDs in (d) were 40 or 80 mg/day (<i>n</i> = 30), 120 mg/day (<i>n</i> = 13), and 160 mg/day (<i>n</i> = 11). MDDs in (e) were 40 or 80 mg/day (<i>n</i> = 30), 120 mg/day (<i>n</i> = 13), 160 mg/day (<i>n</i> = 11). ns, not significant; PANSS, positive and negative syndrome scale.